Danielle Gibbons
Family · Altoona, PANPI 1194737593
Payments from drug & device makers
Across 685 payments — averaging $42.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$17K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$2K
- Johnson & Johnson$972
- Alkermes, Inc.$739
- plus $5K from 28 others
What the payments were for
- Speaking & faculty fees$14,38150%
- Travel & lodging$3601%
- Food & beverage$13,88848%
- Education$2391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 122 | $16,974 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 76 | $1,921 |
| Otsuka America Pharmaceutical, Inc. | 91 | $1,852 |
| AbbVie | 110 | $1,503 |
| Johnson & Johnson | 55 | $972 |
| Alkermes, Inc. | 35 | $739 |
| Neurocrine Biosciences, Inc. | 36 | $723 |
| Lundbeck LLC | 24 | $541 |
| Corium, LLC | 19 | $502 |
| Axsome Therapeutics, Inc. | 18 | $491 |
| E.r. Squibb & Sons, L.L.C. | 19 | $446 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $387 |
| Supernus Pharmaceuticals, Inc. | 9 | $212 |
| Boston Scientific | 3 | $184 |
| Bayer | 2 | $175 |
| Ironshore Pharmaceuticals Inc. | 8 | $153 |
| Merck | 8 | $132 |
| Boehringer Ingelheim | 1 | $121 |
| AstraZeneca | 2 | $114 |
| Noven Therapeutics, LLC | 4 | $85 |
| Sanofi | 1 | $85 |
| Abbott | 1 | $73 |
| Sanofi-aventis U.S. LLC | 1 | $69 |
| Collegium Pharmaceutical, Inc. | 3 | $64 |
| Novo Nordisk | 2 | $62 |
| Inari Medical, Inc. | 1 | $47 |
| Indivior Inc. | 2 | $39 |
| Amgen | 1 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $35 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
| Corcept Therapeutics | 1 | $31 |
| Validus Pharmaceuticals LLC | 1 | $27 |
| Pacira Pharmaceuticals Incorporated | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$14,924
- CAPLYTA$721
- LYBALVI$400
- Azstarys$265
- ABILIFY ASIMTUFII$246
- ABILIFY MAINTENA$246
- Auvelity$125
- VYEPTI$125
- COBENFY$125
- JARDIANCE$121
- Kerendia$121
- INVEGA SUSTENNA$101
How this compares
$28,868 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 21 | $120,767 |
| Abilify MaintenaAripiprazole | 24 | $69,023 |
| RexultiBrexpiprazole | 43 | $65,157 |
| Invega SustennaPaliperidone Palmitate | 16 | $52,507 |
| LatudaLurasidone Hcl | 30 | $42,326 |
| VraylarCariprazine Hcl | 29 | $35,087 |
| TrintellixVortioxetine Hydrobromide | 56 | $26,699 |
| CaplytaLumateperone Tosylate | 11 | $17,380 |
| Clozapine | 124 | $11,539 |
| VyvanseLisdexamfetamine Dimesylate | 25 | $9,537 |
| Bupropion Hcl SrBupropion Hcl | 303 | $5,381 |
| Paliperidone ErPaliperidone | 30 | $4,891 |
| Protriptyline Hcl | 14 | $4,335 |
| Hydroxyzine Hcl | 233 | $4,204 |
| EquetroCarbamazepine | 13 | $4,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,852 | $134,18167 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $16,974 | $120,76721 claims |
| Johnson & JohnsonInvega Sustenna | $972 | $52,50716 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $387 | $36,23681 claims |
| AbbVieVraylar | $1,503 | $35,08729 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,921 | $17,38011 claims |
| Validus Pharmaceuticals LLCEquetro | $27 | $4,00613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Altoona
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.